Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors

International Journal of Cancer

Volumn 105, Issue 1, 2003, Pages 130-135

  Chen, Hui ^a   Isozaki, Koji ^a   Kinoshita, Kazuo ^a   Ohashi, Akiko ^a   Shinomura, Yasuhisa ^a   Matsuzawa, Yuji ^a   Kitamura, Yukihiko ^a   Hirota, Seiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastrointestinal stromal tumors; Imatinib; Inhibition; KIT; Mutation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE MUTATION; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MUTATION; PHOSPHORYLATION; PIPERAZINES; PRECIPITIN TESTS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TIME FACTORS; TRANSFECTION;

EID: 0037457660     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11025     Document Type: Article

References (37)

1. Fishman AP. Gastrointestinal tract. In: Rosai J, ed. Ackerman's surgical pathology. 8th ed. St. Louis: Mosby, 1996. 645-7.
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad-Tunio G, Matsuzawa Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998;279:577-80.
3. Kindblom L-G, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
4. Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji M. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992;69:947-55.
5. Edmonson J, Marks R, Buckner J, Mahoney M. Contrast of response to D-MAP + Sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas [abstract]. Proc Am Soc Clin Oncol 1999;18:541a.
6. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
7. Besmer P, Murphy JE, George PC, Qiu F, Bergold PJ, Lederman L, Snyder HW Jr, Broudeur D, Zuckerman EE, Hardy WD. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-21.
8. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-KIT encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988;335:88-9.
9. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-KIT proto-oncogene. Cell 1988;55:185-92.
10. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS. Identification of a ligand for the c-KIT proto-oncogene. Cell 1990;63:167-74.
11. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human protooncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51.
12. Qiu FH, Ray HP, Brown Y, Barker PE, Jhanwar S, Ruddle FH, Besmer P. Primary structure of c-KIT: relationship with the CSF-1/ PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988;7: 1003-11.
13. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
14. Kissel H, Timokhina I, Hardy MP, Rothschild G, Tajima Y, Soares V, Angeles M, Whitlow SR, Manova K, Besmer P. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J 2000;19:1312-26.
15. Nakahara M, Isozaki K, Hirota S, Miyagawa J-I, Hase-Sawada N, Taniguchi M, Nishida T, Kanayama S, Kitamura Y, Shinomura Y, Matsuzawa Y. A novel gain-of-function mutation of c-KIT gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-5.
16. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H, Kitamura Y. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19:323-4.
17. Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden J-M. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157: 1581-5.
18. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal turnouts. J Pathol 2001;193:505-10.
19. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A, Takabayashi A, Obayashi T, Okuno T, Kinoshita K, Chen H, Shinomura Y, Kitamura Y. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002;122:1493-9.
20. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001;6:233-8.
21. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
22. Okuda K, Weisberg E, Gilliland G, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440-8.
23. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
24. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-KIT receptor tyrosine activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
25. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
26. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
27. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
28. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y. Identification of mutations in the coding sequence of the proto-oncogene c-KIT in a human mast cell leukemia cell line causing ligand-independent activation of c-KIT product. J Clin Invest 1993;92:1736-44.
29. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y. Constitutive activation of c-KIT in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 1996;87: 273-83.
30. Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 2001;98:2808-16.
31. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
32. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher C-DM, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
33. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
34. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, and Longley BJ. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
35. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
36. Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y, Katsuyama T. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001;120:210-5.
37. Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C, Larizza L. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001;92:657-62.